Immuneonco-B (01541) announced interim results
- RevenueRMB25.4M
- Net profitRMB-1.7bn
- Profit attributable to ownersRMB-1.6bn
- Revenue YoY-33.1%
- Net profit YoY-8.4%
- Depreciation & amortisationHK$14.6M
- Capital expenditureHK$-1.3M
- Interest-bearing debtHK$2.3bn
Source Immuneonco-B



